Navigation Links
Orchid Cellmark to Present at the 2009 Bank of America Health Care Conference on May 13th

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc., (Nasdaq: ORCH), today announced that Thomas A. Bologna, President and Chief Executive Officer of Orchid Cellmark, is scheduled to present at the 2009 Bank of America Health Care Conference in New York City on Wednesday, May 13, 2008 at 4:00 p.m. EDT

Mr. Bologna will provide a brief corporate overview and discuss the company's recent and ongoing progress. A link to the live webcast of Mr. Bologna's presentation will be available in the Investors/Calendar of Events section of the company's website at The webcast will be archived through May 29, 2009.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at

All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to the ability to replace the work we previously provided under a subcontractor arrangement, the implementation of government contracts, growing through acquisitions, the potential value of the "mega tender", our potential success in the U.K. National Procurement Plan, expansion of our U.K. facilities, the opportunity for work related to all-arrestee legislation, the potential of property crime testing, operating efficiencies, technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding, competition, intellectual property of others, patent protection, litigation, and the timing and amount of contracts put up for bid. These risks and other additional factors affecting these statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

SOURCE Orchid Cellmark Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
2. Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007
3. Orchid Cellmark to Purchase ReliaGene Technologies, Inc.
4. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
5. Orchid Cellmark to Announce First Quarter 2008 Financial Results on May 8, 2008
6. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
7. Orchid Cellmark to Announce Third Quarter 2008 Financial Results on October 30, 2008
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Avicena Group to Present at Noble Financial Conference
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
Breaking Biology News(10 mins):